Victories and Reflections on Medicines360 Policy Work in 2022

Nearly three years into the pandemic, it is impossible to ignore that the health care policy environment has been forever changed — and that change continues. The pandemic laid bare long-standing inequities in access for people of color, people with low incomes, LGBTQ+ people, women, and people who live at the intersections of these identities. Here at Medicines360, our work is focused on addressing the gaps women face in accessing the medicines they need. While that of course means our work in drug development, manufacturing, and distribution as a nonprofit pharmaceutical company, it also demands that we pay attention to and speak up about policies that could harm or help the women we serve. 

As this work continues, we want to take a minute to share some important policy-related updates from 2022 and a forecast of developments on the horizon as the 118th Congress begins. Foremost, the passage of the year-end omnibus spending bill in December, which includes key provisions for the nonprofit pharmaceutical industry, symbolizes federal support for nonprofit pharma and previews important work to come this year.  

End of Year Victories 

Support for nonprofit pharmaceutical organizations gained robust congressional momentum in 2022 — three pieces of legislation introduced in the 117th Congress include language to support the nonprofit pharmaceutical industry. Two of these pieces – the HHS study on nonprofit pharmaceuticals and the GAO report – were included in the year-end omnibus bill and will lay important bricks in a foundation of federal policy support for nonprofit pharmaceutical organizations.  

  • In March, the Senate HELP Committee advanced the Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics Act (PREVENT Pandemics Act/S.3799) out of Committee, including a critical amendment that would allow the HHS Assistant Secretary for Planning and Evaluation to include nonprofit pharmaceutical companies in a study. This amendment was included in the omnibus spending bill, signed into law by President Biden on December 29.
     
  • In May, Sens. Rosen and Romney (R-UT), announced the introduction of the bipartisan Advancing Affordable Medicines for Families Act (S. 4341), bipartisan legislation which would direct the Government Accountability Office (GAO) to conduct a report on the impact that nonprofit drug companies would have on lowering drug costs, addressing drug shortages, and accelerating the development of new drugs. The report, the language for which is included in the year-end omnibus spending that passed late last year, will also address existing barriers to the success of nonprofit pharmaceutical organizations, and what Congress can do to support them.

  • In June, when the Senate HELP Committee advanced the FDASLA Act (S. 4348) to the full Senate floor with broad bipartisan support, it first added two critical amendments spearheaded by Committee Members Sens. Rosen and Romney. One amendment would call for the same GAO report as S. 4341, while the second amendment would instruct the U.S. Food and Drug Administration (FDA) to hold a public meeting on the value of nonprofit drug organizations, how those nonprofits can help address patient access issues, and whether future user fee processes should be altered to better support their work. 


More Key Updates from 2022 

  • In February, bipartisan cosponsors in the House introduced the Diverse and Equitable Participation in Clinical Trials (DEPICT) Act (H.R. 6584), which would require a “diversity action plan” to ensure representative trial enrollment. While this standalone legislation did not advance, similar language was included in a larger legislative package that passed the House in June. Having conducted the longest clinical trial of an IUD and expanded its indications by including women with diverse demographics such as nulliparous and overweight women, Medicines360 has been actively advocating for increased clinical trial diversity. It’s incredibly encouraging that lawmakers are paying attention to this critical issue.

  • In March, Civica Inc. — a fellow nonprofit pharmaceutical company — announced plans to prioritize patients and advance health equity by providing insulin for no more than $30 a vial. Organizations like Civica and Medicines360 are working to give patients the access to critical care when they need it and showing policymakers a future that is possible with nonprofit pharmaceutical companies incorporated into our healthcare system.

  • In April, amid pushes from state lawmakers to restrict access to sex education and comprehensive reproductive health care, Sen. Marco Rubio (R-FL) forced a failing vote on a Congressional Review Act resolution (S.J.Res.41) that would have nullified the Biden Administration’s rule that reopened the Title X program to all qualified health care providers. Title X – the nation’s family planning program – is a critical program that helps build health equity in this country by expanding access to health care for people with lower incomes. Medicines360 is committed to supporting Title X in all our work.
     
  • In June, reproductive rights champions in the House and Senate introduced the Affordability is Access Act (S.4337 /H.R. 7894) — critical legislation that will require insurance companies to cover, and retailers to not interfere with access to or purchase of, birth control approved by the U.S. Food and Drug Administration (FDA) as safe and effective over-the-counter without a prescription. Medicines360 supports this legislation and is working hard in our advocacy to advance equitable access to contraception for all women. 

  • In late September, Congress passed a five-year user fee agreements (UFAs) reauthorization as part of the Continuing Resolution that funded our government through December 16th, 2022. UFAs are designed to speed up and modernize FDA drug approvals and drug oversight regulations. In a process intended to ensure they are revisited and rethought routinely, UFAs must be reauthorized by Congress every five years.  

  • On August 16, President Biden signed the Inflation Reduction Act into law. This important law was passed via budget reconciliation – a mechanism that allowed the Democratic majority to pass legislation with just 51 votes. While the name doesn’t make this clear, the Inflation Reduction Act contains a variety of critical health care provisions, including requiring the HHS Secretary to negotiate prices for some top-selling drugs covered in Medicare and requiring drug companies to pay rebates if prices rise faster than inflation for drugs used by Medicare beneficiaries. 


What To Watch Moving Forward  

  • Sen. Jacky Rosen (D-NV) introduced the Expanding Access to Affordable Prescription Drugs and Medical Devices Act (S. 2257) in 2021 — a bill designed to support nonprofit pharmaceutical organizations in their efforts to sustainably increase access to affordable medicines for Americans. As the longest-standing nonprofit pharmaceutical organization serving the U.S. market, Medicines360 has proudly applauded this legislation as a significant first step toward supporting nonprofit pharmaceutical organizations in reducing the cost of medicines for patients. We will continue to support Sen. Rosen in her push to advance reforms that support nonprofit pharma in the 118th  Congress. 


Expanding access to critical medicines and devices is at the heart of Medicines360’s work, and we are grateful for this congressional support around the incredible value of that mission. Our policy work, like our work to advance health equity for all women, is just getting started – we look forward to sharing more updates soon. 

About Medicines360

Medicines360, located in San Francisco, California, is a nonprofit global women’s health pharmaceutical organization with a mission to catalyze equitable access to medicines and devices through product development, policy advocacy, and collaboration with global and US partners. Medicines360, through its subsidiary Impact RH360, launched the Avibela Project to expand access to hormonal IUDs in low- and middle-income countries. For more information, visit medicines360.org

Share This

AVIBELA can be made available in the following 88 countries

  1. Algeria
  2. Angola
  3. Bangladesh
  4. Belize
  5. Benin
  6. Bhutan
  7. Botswana
  8. Burkina Faso
  9. Burundi
  10. Cambodia
  11. Cameroon
  12. Cape Verde
  13. Central African Republic
  14. Chad
  15. Comoros
  16. Costa Rica
  17. Cuba
  18. Democratic Republic of the Congo
  19. Djibouti
  20. Dominica
  21. Dominican Republic
  22. Egypt
  23. El Salvador
  24. Equatorial Guinea
  25. Eritrea
  26. Ethiopia
  27. Gabon
  28. Ghana
  29. Grenada
  30. Guatemala
  31. Guinea
  32. Guinea-Bissau
  33. Haiti
  34. Honduras
  35. India
  36. Indonesia
  37. Ivory Coast
  38. Jamaica
  39. Kenya
  40. Lao PDR
  41. Lesotho
  42. Liberia
  43. Libya
  44. Madagascar
  45. Malawi
  46. Malaysia
  47. Maldives
  48. Mali
  49. Mauritania
  50. Mauritius
  51. Mayotte
  52. Morocco
  53. Mozambique
  54. Myanmar
  55. Namibia
  56. Nepal
  57. Nicaragua
  58. Niger
  59. Nigeria
  60. Pakistan
  61. Panama
  62. Papua New Guinea
  63. Philippines
  64. Republic of the Congo
  65. Rwanda
  66. Sao Tome and Principe
  67. Senegal
  68. Seychelles
  69. Sierra Leone
  70. Somalia
  71. South Africa
  72. South Sudan
  73. Sri Lanka
  74. Kitts and Nevis
  75. Lucia
  76. Vincent & the Grenadines
  77. Sudan
  78. Swaziland
  79. Tanzania
  80. Thailand
  81. The Gambia
  82. Timor-Leste
  83. Togo
  84. Tunisia
  85. Uganda
  86. Vietnam
  87. Zambia
  88. Sri Lanka

Tina Raine-Bennett, MD, MPH, FACOG

Chief Executive Officer

Tina Raine-Bennett, MD, MPH, is CEO of Medicines360. Previously, she served as a senior research scientist at the Kaiser Permanente Northern California Division of Research and the research director of the Women’s Health Research Institute. She is a Board-Certified Obstetrician Gynecologist who received her medical training at the University of California, San Diego, and post-graduate residency training and MPH at the University of Washington in Seattle, where she also completed a Robert Wood Johnson Clinical Scholars Fellowship. She was also senior staff physician at Kaiser Permanente and has a special interest in family planning and adolescent reproductive health.

As the director of the Women’s Health Research Institute, Dr. Raine-Bennett focused on expanding research on women’s health within the Division and translating women’s health research into clinical practice and policy within the Ob/Gyn departments in Northern California. She also promoted the involvement of clinicians in research designed to improve the health outcomes and healthcare experiences of women at Kaiser Permanente and women in general.

Prior to Kaiser Permanente, Dr. Raine-Bennett was a professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at University of California, San Francisco (UCSF). She was based at San Francisco General Hospital where she was also the medical director of the New Generation Health Center, a UCSF affiliate site that provides community-based reproductive health services. Dr. Raine-Bennett’s research has focused on contraceptive methods and on elucidating factors that influence contraceptive choice and continuation, and she was principal investigator on NIH grants to assess hormonal contraceptive use predictors and develop interventions to improve contraceptive access.

Her past and current research on emergency contraception has focused on the safety of making emergency contraception more accessible and she conducted a pivotal clinical trial to make emergency contraception available to teens without a prescription. She served on the editorial board of Obstetrics and Gynecology and has over 100 peer-reviewed publications. She was the Treasurer of the Board of Directors for the Society of Family Planning and Society of Family Planning Research Fund. She has also served as an examiner for the American Board of Obstetrics and Gynecology, and on national committees for the American College of Obstetrics and Gynecology and the National Medical Board of Planned Parenthood Federation of America.